Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations

Gewandter, Jennifer S.a,*; Dworkin, Robert H.a; Turk, Dennis C.b; McDermott, Michael P.a; Baron, Ralfc; Gastonguay, Marc R.d; Gilron, Iane; Katz, Nathaniel P.f,g; Mehta, Cyrush; Raja, Srinivasa N.i; Senn, Stephenj; Taylor, Charlesk; Cowan, Penneyl; Desjardins, Paulm; Dimitrova, Rozalinan; Dionne, Raymondo; Farrar, John T.p; Hewitt, David J.q; Iyengar, Smritir; Jay, Gary W.s; Kalso, Eijat; Kerns, Robert D.u; Leff, Richardv; Leong, Michaelw; Petersen, Karin L.x; Ravina, Bernard M.y; Rauschkolb, Christinez; Rice, Andrew S.C.aa; Rowbotham, Michael C.x; Sampaio, Cristinaab; Sindrup, Sren H.acφ; Stauffer, Joseph W.ad; Steigerwald, Ilonaae; Stewart, Jonathanaf; Tobias, Jeffreyag; Treede, Rolf-Detlefah; Wallace, Markai; White, Richard E.aj

doi: 10.1016/j.pain.2014.05.025
Comprehensive review
Buy

Summary This article presents general considerations discussed at an IMMPACT consensus meeting regarding proof-of-concept (POC) clinical trials and major POC trial designs as well as their advantages and limitations when used to evaluate chronic pain treatments.

ABSTRACT Proof-of-concept (POC) clinical trials play an important role in developing novel treatments and determining whether existing treatments may be efficacious in broader populations of patients. The goal of most POC trials is to determine whether a treatment is likely to be efficacious for a given indication and thus whether it is worth investing the financial resources and participant exposure necessary for a confirmatory trial of that intervention. A challenge in designing POC trials is obtaining sufficient information to make this important go/no-go decision in a cost-effective manner. An IMMPACT consensus meeting was convened to discuss design considerations for POC trials in analgesia, with a focus on maximizing power with limited resources and participants. We present general design aspects to consider including patient population, active comparators and placebos, study power, pharmacokinetic–pharmacodynamic relationships, and minimization of missing data. Efficiency of single-dose studies for treatments with rapid onset is discussed. The trade-off between parallel-group and crossover designs with respect to overall sample sizes, trial duration, and applicability is summarized. The advantages and disadvantages of more recent trial designs, including N-of-1 designs, enriched designs, adaptive designs, and sequential parallel comparison designs, are summarized, and recommendations for consideration are provided. More attention to identifying efficient yet powerful designs for POC clinical trials of chronic pain treatments may increase the percentage of truly efficacious pain treatments that are advanced to confirmatory trials while decreasing the percentage of ineffective treatments that continue to be evaluated rather than abandoned.

aUniversity of Rochester, Rochester, NY, USA

bUniversity of Washington, Seattle, WA, USA

cUniversity of Kiel, Kiel, Germany

dMetrum Research Group, Tariffville, CT, USA

eQueen’s University, Kingston, Ontario, Canada

fAnalgesic Solutions, Natick, MA, USA

gTufts University, Boston, MA, USA

hCytel, Boston, MA, USA

iJohns Hopkins University, Baltimore, MD, USA

jCRP Santé, Strassen, Luxembourg

kCP Taylor Consulting, Ann Arbor, MI, USA

lAmerican Chronic Pain Association, Rocklin, CA, USA

mDesjardins Associates and Rutgers University, Newark, NJ, USA

nAllergan, Irvine, CA, USA

oEast Carolina University, Greenville, NC, USA

pUniversity of Pennsylvania, Philadelphia, PA, USA

qMerck, Blue Bell, PA, USA

rEli Lilly, Indianapolis, IN, USA

sVirtuous Pharma, Inc., Raleigh-Durham, NC, USA

tUniversity of Helsinki, Helsinki, Finland

uVA Connecticut Healthcare System, West Haven, CT, USA

vRichard L Leff MD LLC, Chadds Ford, PA, USA

wStanford University, Stanford, CA, USA

xCalifornia Pacific Medical Center, San Francisco, CA, USA

yVoyager Therapeutics, Cambridge, MA, USA

zJohnson and Johnson, Raritan, NJ, USA

aaImperial College, London, UK

abFaculdade de Medicina de Lisboa, Lisbon, Portugal

acUniversity of Southern Denmark, Odense, Denmark

adAlpharma, Piscataway, NJ, USA

aeGrünenthal GMbH, Aachen, Germany

afGlaxoSmithKline, Research Triangle Park, NC, USA

agJazz Pharmaceuticals, Palo Alto, CA, USA

ahHeidelberg University, Mannheim, Germany

aiUniversity of California San Diego, San Diego, CA, USA

ajEndo Pharmaceuticals, Chadds Ford, PA, USA

*Corresponding author. Address: Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Ave., Box 604, Rochester, NY 14642, USA. Tel.: +1 585 276 5661; fax: +1 585 244 7271.

E-mail: jennifer_gewandter@urmc.rochester.edu

Submitted February 25, 2014; revised May 15, 2014; accepted May 21, 2014.

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

© 2014 International Association for the Study of Pain
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website